The potential risk associated with TdP occurs because of the pharmacological inhibition of human ether-a-go-go-related gene (hERG) ion channels, which regulate the rapid component of the delayed rectifier current (IKr) and prolong the QT interval during drug administration, and it may potentially be life-threatening to consumers. The gene discussed is KCNH2; the disease is torsades de pointes.